| Abstract: | Vascular endothelial growth factor (VEGF) plays a crucial role in angiogenesis within solid cancers. Thus, targeting VEGF might be part of a feasible therapy for treating pathological neovascularization, and nanobodies ? derived from heavy chain‐only antibodies occurring within Camelidae ? are a novel class of nanometer‐sized antibodies possessing unique properties that could be developed into a promising therapeutic. However, nanobodies have a very short half‐life in vivo due to their small size. Development of a bivalent nanobody is one way to remediate the half‐life problem of nanobodies. Two identical anti‐VEGF nanobodies were connected using the hinge region of llama IgG2c. The recombinant plasmid (pHEN6c‐bivalent nanobody) was transformed into E.coli WK6 cells and expression of the bivalent nanobody construct was induced with 1mM Isopropyl β‐D‐1‐thiogalactopyranoside (IPTG). Recombinant bivalent nanobody was purified using nickel affinity chromatography and its activity on human endothelial cells was assessed using 3‐(4,5‐Dimethylthiazol‐2‐yr)‐2,5‐diphenyltetrazolium bromide (MTT), tube formation, and cell migration assays. The pharmacokinetic study was performed after intravenous (i.v.) injection of recombinant bivalent nanobody into six‐week‐old C57BL/6 mice. Recombinant bivalent nanobody performed significantly better than monovalent nanobody in inhibiting proliferation, tube formation, and migration of human endothelial cells. Pharmacokinetic results showed a 1.8‐fold longer half‐life of bivalent nanobody in comparison with the monovalent nanobody. These results underscore the potential of recombinant anti‐VEGF bivalent nanobody as a promising tool for development of a novel therapeutic with an extended plasma half‐life for VEGF‐related diseases. |
